Berlin —Pfizer and BioNTech have secured approval for Germany’s first human clinical trials of a possible coronavirus vaccine, entering a global race to develop a defence against the pandemic.

Regulators gave the green light to test the companies’ proposed vaccine on 200 healthy people aged 18 to 55 years in a first stage, and on additional high-risk candidates in a second stage, according to a statement on Wednesday. Shares of BioNTech rose as much as 63% in Frankfurt...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now